Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia.
BACKGROUND
The percentage of myeloperoxidase (MPO)-positive blast cells is associated with prognosis in adult acute myeloid leukemia (AML), but this association is unsubstantiated in pediatric AML.


METHODS
We retrospectively compared cytochemical MPO results with outcome in 154 patients younger than 21 years treated on three consecutive institutional protocols for newly diagnosed AML (1987-2001). Patients with FAB M0 and M7 AML (no MPO expression) or M3 AML (100% MPO expression) and Down's syndrome were excluded.


RESULTS
Median MPO expression was higher in FAB M2 subtype than in other subtypes (P < 0.0001) and differed significantly across cytogenetic risk groups (P = 0.002) with highest MPO expression among those with favorable karyotypes. The percentage of MPO-positive blasts was not significantly associated with the probability of complete remission (P = 0.97), event-free survival (P = 0.72), or survival (P = 0.76) in multivariate analyses that accounted for age, FAB subtype, presenting WBC count, cytogenetic and protocol treatment risk group. In analysis limited to patients with intermediate-risk cytogenetics, higher MPO expression appeared to be associated with improved EFS (P = 0.06) but was not associated with remission induction rate (P = 0.16) or overall survival (P = 0.38).


CONCLUSIONS
The percentage of MPO-positive blast cells is related to FAB subtype in pediatric AML but has limited prognostic relevance.
Roberson
Jessica R
JR
Department of Hematology-Oncology, St. Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, Tennessee, USA.
Onciu
Mihaela
M
Pounds
Stanley
S
Rubnitz
Jeffrey E
JE
Pui
Ching-Hon
CH
Razzouk
Bassem I
BI
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D015415:Biomarkers; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000097:blood* / Q000145:classification / Q000235:genetics / Q000401:mortality; D008297:Male; D022423:Myeloid Cells / Q000201:enzymology*; D014411:Neoplastic Stem Cells / Q000201:enzymology*; D009195:Peroxidase / Q000097:blood*; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk; D016019:Survival Analysis
D015415:Biomarkers; D009195:Peroxidase